Edition:
United States

Aurobindo Pharma Ltd (ARBN.NS)

ARBN.NS on National Stock Exchange of India

714.10INR
3:27am EST
Change (% chg)

Rs-10.80 (-1.49%)
Prev Close
Rs724.90
Open
Rs730.80
Day's High
Rs730.80
Day's Low
Rs714.00
Volume
742,017
Avg. Vol
2,200,338
52-wk High
Rs895.00
52-wk Low
Rs582.00

Select another date:

Fri, Dec 16 2016

India's Aurobindo shares hit nine-month low on US price-fixing lawsuit

MUMBAI Indian drugmaker Aurobindo Pharma Ltd's shares hit their lowest in more than nine months on Friday after the company was named in a lawsuit alleging it colluded with other drugmakers to fix prices of two commonly used drugs in the United States.

BRIEF-Aurobindo Pharma unit Arrow Generiques to buy select assets in France from Teva

* Aurobindo Pharma Ltd says Arrow Generiques to acquire select assets in France from Teva

BRIEF-India's Aurobindo Pharma Q2 consol net profit rises 33.5 pct

* Sept quarter consol net profit 6.06 billion rupees Source text for Eikon: http://bit.ly/2fS1r1x Further company coverage: (Reporting by Promit Mukherjee)

Founders of India's Aurobindo Pharma to sell up to $135 mln of shares -term sheet

MUMBAI, Oct 6 The founders of India's Aurobindo Pharma are selling shares worth up to $135 million in a block trade on Friday, according to a deal term sheet seen by Reuters.

BRIEF-Aurobindo Pharma gets USFDA tentative approval for Dolutegravir

* Aurobindo Pharma receives USFDA tentative approval for Dolutegravir, allowing the product to be launched in the PEPFAR market Source text: (http://bit.ly/2cTnfIs) Further company coverage: (Bengaluru newsroom)

Indian shares edge up but caution prevails ahead of Fed comments

Aug 24 Indian shares closed slightly higher on Wednesday, led by drug maker Aurobindo Pharma Ltd after stellar quarterly results, but sentiment remained edgy as investors awaited further cues on whether the U.S. Federal Reserve will raise interest rates this year.

Indian shares edge up; caution prevails ahead of Yellen speech

Aug 24 Indian shares crept up on Wednesday, led by drug maker Aurobindo Pharma Ltd after stellar quarterly results, but sentiment remained edgy as investors awaited further clues on whether the Federal Reserve will raise U.S. interest rates this year.

Select another date: